FDA approves Sarclisa for patients with relapsed refractory multiple myeloma

3 March 2020

Some eight weeks earlier than expected, the US Food and Drug Administration has approved Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Sarclisa is expected to be available to patients in the USA shortly, said the drug’s developer, French pharma major Sanofi (Euronext: SAN) late Monday, noting that Sarclisa is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells. It is the first cancer treatment wholly-owned by Sanofi to win approval in the past decade.

Sanofi, whose shares were up more than 2% at 87.36 euros mid-morning today, estimates the total third-line market opportunity in the USA and major European markets at $3.4 billion. The second-line market estimate is much larger, at $6 billion. Sanofi hopes to take a slice of the market dominated by Johnson & Johnson’s (NYSE: JNJ) Darzalex (daratumumab).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK